United Therapeutics Corporation

Equities

UTHR

US91307C1027

Market Closed - Nasdaq Other stock markets 21:00:00 13/06/2025 BST			5-day change	1st Jan Change
283.35 ^USD	-0.98%		-13.03%	-19.69%

06-10	Insmed Shares Rise After Phase 2b Trial of Treprostinil Inhalation Powder in PAH Meets Endpoints	MT
06-10	Insmed's drug for rare lung disease achieves 'home run' in mid-stage trial	RE

United Therapeutics Corporation, Q1 2024 Earnings Call, May 01, 2024

Published on 01/05/2024 at 14:00

Presentation Operator Message
Operator (Operator)

Good morning, and welcome to the United Therapeutics Corporation First Quarter 2024 Earnings Webcast. My name is Danielle, and I will be your

This article is reserved for subscribers

Unlock the article : SUBSCRIBE!

Already a customer? Log In

Latest news about United Therapeutics Corporation

Insmed Shares Rise After Phase 2b Trial of Treprostinil Inhalation Powder in PAH Meets Endpoints	06-10	MT
Insmed's drug for rare lung disease achieves 'home run' in mid-stage trial	06-10	RE
Liquidia, United Therapeutics Shares Fall Pre-Bell After Rival Insmed's Phase 2b PAH Trial Meets Endpoints	06-10	MT
Liquidia Set to Make First Commercial Shipment of Yutrepia for Pulmonary Hypertension	06-02	MT
Cantor Fitzgerald Initiates United Therapeutics at Overweight With $405 Price Target	06-02	MT
Liquidia Receives FDA Approval on Yutrepia for Treatment of Pulmonary Hypertension	05-23	MT
Liquidia Faces Patent Litigation Filed by United Therapeutics	05-12	MT
Liquidia Says New Litigation Filed Against Co In U.S.	05-12	RE
United Therapeutics Corporation, Q1 2025 Earnings Call, Apr 30, 2025	04-30
United Therapeutics Q1 Earnings, Revenue Rise	04-30	MT
Earnings Flash (UTHR) United Therapeutics Posts Q1 Revenue $794.4M, vs. FactSet Est of $729.3M	04-30	MT
United Therapeutics Corporation Reports Earnings Results for the First Quarter Ended March 31, 2025	04-30	CI
United Therapeutics Enters Credit Agreement With Wells Fargo - SEC Filing	04-28	RE
United Therapeutics Corporation Announces Credit Agreement Established for A $2.5 Billion Revolving Facility	04-28	CI
Liquidia Corp Unit Files Patent Infringement Action Against United Therapeutics	04-22	RE
BofA Securities Upgrades United Therapeutics to Neutral From Underperform	04-21	MT
United Therapeutics Insider Sold Shares Worth $3,121,543, According to a Recent SEC Filing	04-21	MT
United Therapeutics Insider Sold Shares Worth $1,138,200, According to a Recent SEC Filing	04-08	MT
United Therapeutics Insider Sold Shares Worth $3,367,984, According to a Recent SEC Filing	04-07	MT
United Therapeutics Insider Sold Shares Worth $796,991, According to a Recent SEC Filing	03-25	MT
UBS Adjusts Price Target on United Therapeutics to $410 From $440, Maintains Buy Rating	03-18	MT
United Therapeutics Corporation Presents at Leerink?s Global Healthcare Conference 2025, Mar-11-2025 10:00 AM	03-11
United Therapeutics Corporation Presents at TD Cowen 45th Annual Healthcare Conference, Mar-03-2025 01:50 PM	03-03
Stocks in motion: Intuit and Axon rise on great results, Applovin tumbles on short-seller attack	02-26
Correction: United Therapeutics Q4 Net Income, Revenue Rise	02-26	MT